Amneal Pharmaceuticals (NYSE:AMRX) updated its FY19 earnings guidance on Monday. The company provided earnings per share guidance of $0.52-0.62 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.61. Amneal Pharmaceuticals also updated its FY 2019 guidance to $0.52-0.62 EPS.
A number of research firms have weighed in on AMRX. Royal Bank of Canada lowered Amneal Pharmaceuticals from an outperform rating to a sector perform rating and reduced their target price for the stock from $11.00 to $6.00 in a research note on Thursday, July 11th. Cantor Fitzgerald reduced their target price on Amneal Pharmaceuticals from $35.00 to $14.00 and set an overweight rating on the stock in a research note on Wednesday, June 12th. SunTrust Banks reiterated a buy rating and issued a $5.00 target price on shares of Amneal Pharmaceuticals in a research note on Tuesday. Barclays set a $5.00 target price on Amneal Pharmaceuticals and gave the stock a hold rating in a research note on Thursday, July 11th. Finally, Piper Jaffray Companies upgraded Amneal Pharmaceuticals from a neutral rating to an overweight rating and set a $11.00 target price on the stock in a research note on Monday, July 8th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have issued a buy rating to the stock. Amneal Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $12.13.
Shares of Amneal Pharmaceuticals stock traded down $0.14 during trading on Wednesday, hitting $2.85. 68,697 shares of the stock traded hands, compared to its average volume of 2,900,298. The stock has a market cap of $854.25 million, a price-to-earnings ratio of 3.01, a P/E/G ratio of 0.29 and a beta of 1.41. The company has a current ratio of 2.11, a quick ratio of 1.37 and a debt-to-equity ratio of 3.44. Amneal Pharmaceuticals has a 52-week low of $2.78 and a 52-week high of $24.48. The firm’s fifty day moving average is $5.03.
In other Amneal Pharmaceuticals news, SVP Pradeep Bhadauria purchased 7,000 shares of the stock in a transaction on Wednesday, May 15th. The stock was acquired at an average price of $8.48 per share, with a total value of $59,360.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Andrew S. Boyer purchased 19,000 shares of the stock in a transaction on Monday, May 13th. The stock was acquired at an average cost of $9.46 per share, with a total value of $179,740.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 1,683,300 shares of company stock worth $5,379,892. 26.34% of the stock is owned by corporate insiders.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Further Reading: What Are Cryptocurrencies?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.